A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

In brief

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Key facts

Study ID

NCT07439653

Run by

TORL Biotherapeutics, LLC

People needed

155

Starts

2026-03-31

Expected to finish

2029-09-30

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
• Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
• At least 1 measurable lesion per Lugano criteria.
• Tumor tissue is available.
• Adequate organ function

You may not qualify if…

• T-cell lymphoma
• CLL or SL
• Burkitt lymphoma and high-grade B-cell lymphoma
• CNS involvement
• Peripheral neuropathy > Grade 2
• Uncontrolled medical conditions
• Viral infections

Where it is running

• UCLA — Santa Monica, California, United States (enrolling)
• Stanford University — Stanford, California, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.